FDA Staying The Course Under Ostroff; Hamburg’s Concerns Remain Focus
This article was originally published in The Tan Sheet
Acting FDA Commissioner Ostroff says he does not envision new major priorities that would emerge in the short-term. The former FDA chief scientist is non-committal about submitting his name as a candidate for permanent commissioner.
You may also be interested in...
Hamburg, The Atypical Commissioner, Receives Atypically Fond Farewell
Margaret Hamburg’s background in public health, as opposed to academic medicine, was off-putting to some in pharma initially, but she leaves the agency in March with high drug approval numbers, initiatives to improve the OTC monograph and switch programs and increased enforcement in the supplement manufacturing arena.
Learning To Drive The ‘Chariot’: FDA Deputy Califf’s New Role
Renowned clinical trialist and cardiologist will become deputy commissioner for medical products and tobacco, a complicated and challenging position.
US FDA Holds First Hybrid Meeting With Industry
A Type A meeting was held in-person with a virtual contingent, the FDA clarified to the Pink Sheet. Several other meeting requests received were eligible, but did not seek an in-person session.